Frontiers in Immunology · Nov 18, 2026
Polygenic Cooperativity in Myeloid Malignancies: From Clonal Architecture to Precision Therapy
By Juan Chen
The profound inter-and intra-tumour heterogeneity of hematological malignancies, which is driven by the cooperation of multiple driver lesions acting within a Darwinian clonal-evolution framework, is the main barrier to curative therapies. This review aims to systematically elucidate the pathogenesis, clonal evolutionary trajectories and profound implications for precision medicine in hematological malignancies through the lens of polygenic cooperativity and clonal evolution. First, the multi-step evolutionary model from clonal haematopoiesis of indeterminate potential (CHIP) to overt malignancy is explored. Core molecular principles such as functional complementation, amplification and the temporal dependency of mutation synergy are emphasised, while distinguishing these from multistep mutation acquisition, branching subclonal evolution and biallelic tumour-suppressor loss. Next, we examine how distinctive clinical phenotypes and prognoses emerge from specific co-mutation combinations across major disease spectra. Building on this foundation, this paper focuses on novel, co-mutation-guided therapeutic strategies. These include combination targeted therapies against synergistic mutation pairs; multi-gene profile-based matching for immunotherapy; and high-sensitivity minimal residual disease (MRD) monitoring, which accounts for clonal hematopoiesis of indeterminate potential (CHIP) interference. Foundational concepts including the routes of CHIP-to-MDS/AML transformation, the influence of mutational timing and the application of single-cell and spatial multi-omics to clonal architecture are introduced to support the disease-specific analyses that follow. Finally, this review discusses the technical challenges and future directions in the field, envisaging artificial intelligence–driven modelling as a means to integrate polygenic cooperation with clonal architecture for clinical application. The aim is to provide a theoretical framework and forward-looking insights to develop more effective, personalised therapies that could transform the standard of care.